Report Outlook
Market Size | CAGR | Dominating Region |
---|---|---|
USD 20.01 Billion by 2029 | 14.60% | North America |
By Type | By Application | By Region |
---|---|---|
|
|
|
SCOPE OF THE REPORT
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Overview
The global autologous stem cell and non-stem cell-based therapies market is expected to grow at 14.60 % CAGR from 2020 to 2029. It is expected to reach above USD 20.01 Billion by 2029 from USD 5.87 Billion in 2020.
In autologous stem cell transplantation, which is also referred to as autogenetic, autogenic, or autogenous stem cell transplantation or auto-SCT, the undifferentiated cells or stem cells are taken from a person, gathered, and then later given back to the same person. In certain instances, cardiac cells are successfully employed to repair the damage caused by heart attacks, despite the fact that hematopoietic stem cells—the precursors of the blood cells—are most frequently used in hematopoietic stem cell transplantation. There are two types of stem cell transplantation: allogenic stem cell transplantation and autologous stem cell transplantation. In the latter, the stem cell donor and recipient are different individuals.
ATTRIBUTE | DETAILS |
Study period | 2020-2029 |
Base year | 2021 |
Estimated year | 2022 |
Forecasted year | 2022-2029 |
Historical period | 2018-2020 |
Unit | Value (USD Billion) |
Segmentation | By Type, Application and region. |
By Type |
|
By Application |
|
By Region |
|
It has been shown that stem cell technology is a fast-evolving field with significant applications in tissue engineering, gene therapy, cellular therapies, regenerative medicine, developmental cell biology, and nanotechnology, among other fields. Stem cells can take the role of cells and tissues in the treatment of a variety of illnesses, including Parkinson’s disease, arthritis, and spinal cord injury, among others. With abilities including self-renewal, pluripotency, and differentiation, stem cells play a key role in the regeneration of tissues and organs. In drug targeting and regenerative medicine, stem cells are being developed as a therapeutic tool with a variety of uses, from the treatment of congenital illnesses to the treatment of neurological diseases and cancers. Stem cells now have a firm future in medicine because to these technical advances.
Unavailability of cancer-related medical knowledge. The body could suffer from the addition of progenitor cells if the growth of tumors is sped up. Thus, further study and research are currently required to develop cell therapy for cancer-related illnesses. Quality matters a lot when it comes to stem cells. In comparison to younger individuals, older adults have a lesser ability to produce bone marrow stem cells. The likelihood that a patient would produce a high number of stem cells decreases beyond certain age.
Governments from underdeveloped and developing countries funding the research in fields of stem cell therapies. Those nations are having poor health care and it provide great opportunity as the need for advanced healthcare services and novel medical equipment in the respective healthcare systems of these nations is anticipated to be driven by reasons such as the rising geriatric population, the rising incidence of target diseases, and the rising demand for surgical procedures. In the upcoming years, this is anticipated to present participants in the autologous stem cell and non-stem cell-based therapies market with prospective growth prospects.
Nearly every industry was impacted by COVID-19, a global public health disaster that had never before been seen. Over the course of the forecast period, the effects are expected to have a long-term effect on the expansion of a number of end-use industries. But for the Autologous Stem Cell and Non-Stem Cell Based Therapies market it was different market has seen during pandemic period. The reason for growth during pandemic is increased adoption in Autologous Stem Cell and Non-Stem Cell Based Therapies in many clinical trials to find a solution for the Covid 19 research were motivated to use this method so that it will give a sure shot long term solution for Covid 19.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Segment Analysis
In segmentation there are 2 types by type and by application. The use of stem cell therapies for the treatment of cancer and the rising incidence of the disease are anticipated to drive market expansion. Cancer rates may increase, according to the World Cancer Report. It also demonstrates how public health initiatives, healthy lifestyle choices, and government policies can arrest this trend and eliminate up to one-third of cancer cases globally. Ignoring elements like smoking, eating poorly, being physically inactive, and having fewer children in economically developing nations, the increase in mortality is primarily related to population growth and ageing. Stem cell treatment, which encompasses all operations that utilize stem cells, has shown a viable solution in the fight against cancer. due to the possibility that by narrowing the off-target events, its enhanced target on tumors may enhance the therapeutic efficacy of other medicines. Preclinical trials are currently testing a wide range of stem cell-based approaches for the treatment of cancer, and they offer both enormous promise and important obstacles.
By type, there are 2 types autologous stem cells and autologous non-stem cell-based therapies. In autologous stem cell therapy or stem cell transplants, healthy blood stem cells from the patient’s own body are used to treat or replace diseased or damaged bone marrow. Autologous platelet-rich plasma (PRP), a non-stem cell-based therapy that contains fibrin and high quantities of growth factors, may promote the healing of chronic wounds. Here autologous stem cell therapy is dominant.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Players
The Autologous Stem Cell and Non-Stem Cell Based Therapies Market key players include BrainStorm Cell Limited, Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science Inc., Opexa Therapeutics Inc., Orgenesis Inc, Regeneus Ltd., U.S. Stem Cell Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc.
For corporate expansion, these key leaders are implementing strategic formulations such as new product development and commercialization, commercial expansion, and distribution agreements. Moreover, these participants are substantially spending on product development, which is fueling revenue generation.
Industry Development:
- Jan 2023 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn’s placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community. The specimens are being submitted to the biorepository in connection with a$500,000 grant previously awarded to BrainStorm by The ALS Association and I AM ALS, to support biomarker research.
- Jan 2022 Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a publically traded biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS.
Who Should Buy? Or Key stakeholders
- Investors
- Raw Materials Manufacturer
- Healthcare Companies
- Research Organizations
- Regulatory Authorities
- Institutional & retail players
- Others
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Analysis
The Autologous Stem Cell and Non-Stem Cell Based Therapies Market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN, and Rest of APAC
- Europe: includes the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe
- South America: includes Brazil, Argentina, and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and the Rest of MEA
The largest portion of the market for autologous stem cell and non-stem cell-based therapies was accounted for by North America. This is why the hazards associated with the treatment are kept to a minimum. The fact that these medications may effectively treat a large range of infectious disorders also contributes to their high demand. As there is no need for a third-party donor with autologous stem cell and non-stem cell therapies, the procedure is more convenient and less contagious. These elements are probably going to help the North American market expand.
The region with the highest growth is anticipated to be Asia Pacific, nevertheless. Countries like China, India, Malaysia, and Vietnam will lead the demand in this region. As autologous stem cell and non-stem cell therapies help with the effective management of cardiovascular disorders as well, the demand is projected to increase. The Asia Pacific autologous stem cell and non-stem cell based therapies market is anticipated to rise as a result of expanding healthcare infrastructure as well as increased market player collaboration and acquisition.
Key Market Segments: Autologous Stem Cell and Non-Stem Cell Based Therapies Market
Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Type, 2020-2029, (USD Billion).
- Autologous Stem Cell
- Autologous Non-Stem Cell
Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Application, 2020-2029, (USD Billion).
- Cancer
- Neurodegenerative Disorders
- Cardiovascular Disease
- Orthopedic Diseases
Autologous Stem Cell and Non-Stem Cell Based Therapies Market By Region, 2020-2029, (USD Billion).
- North America
- Asia Pacific
- Europe
- South America
- Middle East and Africa
Important Countries in All Regions Are Covered.
Exactitude Consultancy Services Key Objectives:
- Increasing sales and market share
- Developing new technology
- Improving profitability
- Entering new markets
- Enhancing brand reputation
Key Question Answered
- What is the expected growth rate of the Autologous Stem Cell and Non-Stem Cell Based Therapies market over the next 7 years?
- Who are the major players in the Autologous Stem Cell and Non-Stem Cell Based Therapies market and what is their market share?
- What are the end-user industries driving demand for market and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-pacific, middle east, and Africa?
- How is the economic environment affecting the Autologous Stem Cell and Non-Stem Cell Based Therapies market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the Autologous Stem Cell and Non-Stem Cell Based Therapies market?
- What is the current and forecasted size and growth rate of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market?
- What are the key drivers of growth in the Autologous Stem Cell and Non-Stem Cell Based Therapies market?
- What are the distribution channels and supply chain dynamics in the Autologous Stem Cell and Non-Stem Cell Based Therapies market?
- What are the technological advancements and innovations in the Autologous Stem Cell and Non-Stem Cell Based Therapies market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the Autologous Stem Cell and Non-Stem Cell Based Therapies market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the Autologous Stem Cell and Non-Stem Cell Based Therapies market?
- What are the product offerings and specifications of leading players in the market?
- What is the pricing trend of Autologous Stem Cell and Non-Stem Cell Based Therapies in the market and what is the impact of raw material prices on the price trend?
Table of Content
- Introduction
- Market Definition
- Market Segmentation
- Research Timelines
- Assumptions and Limitations
- Research Methodology
- Data Mining
- Secondary Research
- Primary Research
- Subject-Matter Experts’ Advice
- Quality Checks
- Final Review
- Data Triangulation
- Bottom-Up Approach
- Top-Down Approach
- Research Flow
- Data Sources
- Data Mining
- Executive Summary
- Market Overview
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market outlook
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of Covid-19 on Autologous Stem Cell and Non-Stem Cell Based Therapies Market
- Porter’s five forces model
- Threat from new entrants
- Threat from substitutes
- Bargaining power of suppliers
- Bargaining power of customers
- Degree of competition
- Industry value chain Analysis
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market outlook
- GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE, 2020-2029, (USD BILLION).
- Autologous Stem Cell
- Autologous Non-Stem Cell
- GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION, 2020-2029, (USD BILLION).
- Cancer
- Neurodegenerative Disorders
- Cardiovascular Disease
- Orthopedic Diseases
- GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY REGION, 2020-2029, (USD BILLION).
- North America
- US
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Colombia
- Rest Of South America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest Of Europe
- Asia Pacific
- India
- China
- Japan
- South Korea
- Australia
- South-East Asia
- Rest Of Asia Pacific
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest Of Middle East and Africa
- North America
- Company Profiles*
(Business Overview, Company Snapshot, Products Offered, Recent Developments)
- BrainStorm Cell Limited
- Cytori Therapeutic Inc.
- Dendreon Pharmaceutical LLC
- Fibrocell Science Inc
- Opexa Therapeutic Inc.
- Orgenesis Inc
- Regeneus Ltd.
- S. Stem Cell Inc.
- Castle Creek Biosciences Inc.
- Gilead Sciences Inc.
*The Company List Is Indicative
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLION), 2020-2029
TABLE 2Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 3Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY REGION (USD BILLIONS), 2020-2029
TABLE 4Â Â Â Â Â Â Â NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 5Â Â Â Â Â Â Â NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 6Â Â Â Â Â Â Â NORTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 7Â Â Â Â Â Â Â US AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 8Â Â Â Â Â Â Â US AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 9Â Â Â Â Â Â Â CANADA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (BILLIONS), 2020-2029
TABLE 10Â Â Â Â Â CANADA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 11Â Â Â Â Â MEXICO AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 12Â Â Â Â Â MEXICO AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 13Â Â Â Â Â SOUTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 14Â Â Â Â Â SOUTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 15Â Â Â Â Â SOUTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 16Â Â Â Â Â BRAZIL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 17Â Â Â Â Â BRAZIL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 18Â Â Â Â Â ARGENTINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 19Â Â Â Â Â ARGENTINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 20Â Â Â Â Â REST OF SOUTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 21Â Â Â Â Â REST OF SOUTH AMERICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 22Â Â Â Â Â ASIA -PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 23Â Â Â Â Â ASIA -PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 24Â Â Â Â Â ASIA -PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 25Â Â Â Â Â INDIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 26Â Â Â Â Â INDIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 27Â Â Â Â Â CHINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 28Â Â Â Â Â CHINA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 29Â Â Â Â Â JAPAN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 30Â Â Â Â Â JAPAN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 31Â Â Â Â Â SOUTH KOREA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 32Â Â Â Â Â SOUTH KOREA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 33Â Â Â Â Â AUSTRALIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 34Â Â Â Â Â AUSTRALIA HYBRID FUNCTIONBY APPLICATION (USD BILLION), 2020-2029
TABLE 35Â Â Â Â Â AUSTRALIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY FUNCTION (USD BILLIONS), 2020-2029
TABLE 36Â Â Â Â Â AUSTRALIA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY organization size (USD BILLION), 2020-2029
TABLE 37Â Â Â Â Â REST OF ASIA PACIFIC AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 38Â Â Â Â Â REST OF ASIA PACIFIC HYBRID FUNCTIONBY APPLICATION (USD BILLION), 2020-2029
TABLE 39Â Â Â Â Â EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 40Â Â Â Â Â EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 41Â Â Â Â Â EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 42Â Â Â Â Â GERMANY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 43Â Â Â Â Â GERMANY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 44Â Â Â Â Â UK AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 45Â Â Â Â Â UK AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 46Â Â Â Â Â FRANCE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 47Â Â Â Â Â FRANCE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 48Â Â Â Â Â ITALY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 49Â Â Â Â Â ITALY AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 50Â Â Â Â Â SPAIN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 51Â Â Â Â Â SPAIN AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 52Â Â Â Â Â REST OF EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 53Â Â Â Â Â REST OF EUROPE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 54Â Â Â Â Â MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 55Â Â Â Â Â MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 56Â Â Â Â Â MIDDLE EAST ABD AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY COUNTRY (USD BILLION), 2020-2029
TABLE 57Â Â Â Â Â UAE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 58Â Â Â Â Â UAE AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 59Â Â Â Â Â SOUTH AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 60Â Â Â Â Â SOUTH AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
TABLE 61Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY TYPE (USD BILLIONS), 2020-2029
TABLE 62Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES MARKET BY APPLICATION (USD BILLION), 2020-2029
LIST OF FIGURES
FIGURE 1Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â Â Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â Â Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â Â Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â Â Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY TYPE, USD BILLION, 2020-2029
FIGURE 9Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY APPLICATION, USD BILLION, 2020-2029
FIGURE 10Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY REGION, USD BILLION, 2020-2029
FIGURE 11          PORTER’S FIVE FORCES MODEL
FIGURE 12Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY TYPE, USD BILLION, 2021
FIGURE 13Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY APPLICATION, USD BILLION, 2021
FIGURE 14Â Â Â Â Â Â Â Â Â Â GLOBAL AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPIES BY REGION, USD BILLION, 2021
FIGURE 15Â Â Â Â Â Â Â Â Â Â MARKET SHARE ANALYSIS
FIGURE 16Â Â Â Â Â Â Â Â Â Â BRAINSTORM CELL LIMITED: COMPANY SNAPSHOT
FIGURE 17Â Â Â Â Â Â Â Â Â Â CYTORI THERAPEUTICS INC.: COMPANY SNAPSHOT
FIGURE 18Â Â Â Â Â Â Â Â Â Â DENDREON PHARMACEUTICALS LLC.: COMPANY SNAPSHOT
FIGURE 19Â Â Â Â Â Â Â Â Â Â FIBROCELL SCIENCE INC.: COMPANY SNAPSHOT
FIGURE 20Â Â Â Â Â Â Â Â Â Â OPEXA THERAPEUTICS INC.: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â Â Â Â Â Â Â ORGENESIS INC.: COMPANY SNAPSHOT
FIGURE 22Â Â Â Â Â Â Â Â Â Â REGENEUS LTD.: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â Â Â Â Â Â Â U.S. STEMM CELL INC.: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â Â Â Â Â Â Â CASTLE CREEK BIOSCIENCES INC.: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â Â Â Â Â Â Â GILEAD SCIENCES INC.: COMPANY SNAPSHOT
FAQ
The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to grow at 14.6 % CAGR from 2020 to 2029. It is expected to reach above USD 20.01 Billion by 2029 from USD 5.87 Billion in 2020.
North America held more than 48% of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market revenue share in 2020 and will witness tremendous expansion during the forecast period.
One of the primary drivers is the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders, which require innovative and effective treatments. Stem cell therapies have the potential to address unmet medical needs and provide new treatment options for these conditions.
The Health Care sector is major sector where the application of Autologous Stem Cell and Non-Stem Cell Based Therapies has seen more.
The Markets largest share is in the North America region.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.